Create a benzodiazepine deprescribing protocol: eligibility, taper algorithms, supports,…
- User
Create a benzodiazepine deprescribing protocol: eligibility, taper algorithms, supports, and relapse prevention.
- Assistant
Benzodiazepine Deprescribing Protocol
Important Disclaimer: This protocol is for informational purposes only and is based on established guidelines (e.g., Ashton Manual, NICE, APA, and VA/DoD). It is not a substitute for personalized medical advice. Deprescribing benzodiazepines (BZDs) should only be managed by a qualified healthcare provider, with close monitoring for withdrawal symptoms (e.g., anxiety, insomnia, seizures). Individualize based on patient history, dose, duration, comorbidities, and half-life of the BZD. Obtain informed consent and baseline assessments.
1. Eligibility Criteria
Assess patients for deprescribing if they meet most of these criteria. Screen for contraindications (e.g., acute psychosis, uncontrolled epilepsy, pregnancy).
Inclusion Criteria
- Duration of use: ≥4 weeks (ideally >6 months for chronic users).
- Stable condition: Underlying condition (e.g., anxiety, insomnia) well-controlled for ≥3 months; no acute decompensation.
- Dose: On a stable, relatively low-to-moderate dose (e.g., ≤40 mg diazepam equivalents/day).
- Motivation: Patient understands risks/benefits, is motivated, and commits to follow-up.
- Support system: Access to primary care, mental health support, and social resources.
- No high-risk factors: Stable physical health; no history of severe withdrawal (unless previously managed successfully).
Exclusion/High Caution Criteria (Delay or Refer)
Criterion Action High dose (>60 mg diazepam equiv./day) Switch to long-acting BZD first Pregnancy/lactation Specialist consult (e.g., taper slowly or alternatives) History of seizures/alcohol withdrawal Inpatient taper if severe Active substance use disorder Stabilize SUD first Severe psychiatric instability Stabilize before taper Short-acting BZD only (e.g., alprazolam) without switch Switch to diazepam Pre-Taper Workup:
- Labs: LFTs, renal function, CBC, electrolytes.
- Assessments: GAD-7, PHQ-9, ISI (Insomnia Severity Index), COWS (if concurrent opioids).
- ECG if cardiac history.
- Document BZD dose in diazepam equivalents (see Table below).
Diazepam Equivalents (approximate conversion factors):
BZD 10 mg Diazepam Equivalent Alprazolam (Xanax) 0.5–1 mg Clonazepam (Klonopin) 0.5 mg Lorazepam (Ativan) 1–2 mg Oxazepam 20–30 mg Temazepam (Restoril) 20 mg 2. Taper Algorithms
Principles:
- Slow taper: 5–10% dose reduction every 1–4 weeks (slower for higher doses/long-term use).
- Switch to long-acting BZD (diazepam preferred; half-life 20–100 hrs) for smoother withdrawal.
- Liquid formulation or pill-splitting for fine adjustments.
- Monitor weekly/biweekly: Withdrawal symptoms (CIWA-BZD scale or custom: anxiety, tremor, sweating, insomnia, perceptual changes). Hold or slow if severe.
- Duration: 6–18 months typical; faster (3–6 months) for short-term users.
- Adjuncts: See Section 3.
Step 1: Equivalent Dose Switch (if not already on diazepam)
- Calculate total daily diazepam equivalent.
- Switch over 1–2 weeks (25–50% swap per step).
- Example: 2 mg alprazolam/day = 40 mg diazepam/day.
Step 2: Taper Schedule
Standard Outpatient Taper (adjust ± based on symptoms):
Phase % Reduction Interval Example: Starting 40 mg Diazepam/Day 1 5–10% 1–2 weeks 40 → 36 → 32 mg 2–6 5–10% 2–4 weeks 32 → 28 → 24 → 20 → 16 → 12 mg 7–10 5% 4 weeks 12 → 10 → 8 → 6 → 4 mg Final 1–2 mg 2–4 weeks/step 4 → 2 → 1 → 0.5 → 0 mg - High-Dose (>60 mg equiv.): Reduce by 2–5 mg/week initially; inpatient if >100 mg.
- Short-Acting Only: No switch? Taper 10–25% every 1–2 weeks, but riskier (protracted symptoms).
- PRN Use: Eliminate PRN first.
- Protracted Withdrawal: If symptoms persist >6 months post-taper, supportive care (no reinstatement).
Inpatient Taper (for severe dependence/high risk):
- Initial stabilization.
- Reduce 10–20% every 2–4 days.
- Carbamazepine or other adjuncts if seizures risk.
3. Supports During Taper
Multimodal support reduces dropout (up to 50% success rate with supports).
Pharmacologic
Symptom Options Anxiety/Insomnia Hydroxyzine, low-dose trazodone, melatonin, gabapentin (taper after) Muscle spasms Baclofen, tizanidine Seizure prophylaxis If history: carbamazepine 200–600 mg/day (taper post-BZD) Avoid: Other sedatives, beta-blockers alone Non-Pharmacologic
- Psychotherapy: CBT-I (insomnia), CBT-anxiety (8–12 sessions); ACT or DBT.
- Lifestyle:
Domain Strategies Sleep Hygiene Fixed schedule, no screens, exercise Exercise 150 min/week aerobic + yoga/tai chi Nutrition Caffeine limit, balanced diet Mindfulness Apps (Headspace), daily meditation - Monitoring: Weekly telehealth; patient diary (symptoms, adherence).
- Groups: BZD support (e.g., Benzodiazepine Information Coalition online).
4. Relapse Prevention
Goal: Sustain abstinence; relapse risk highest first 6–12 months.
Strategies
- Education: Teach withdrawal timeline (acute: 1–4 weeks; protracted: months–years). Normalize symptoms.
- Follow-Up: Monthly x3 months, then q3–6 months x1 year.
- Therapy Maintenance: Ongoing CBT or support groups.
- Lifestyle Anchors:
- Trigger identification (stress, sleep loss).
- Coping plan: "HALT" (Hungry? Angry? Lonely? Tired?).
- Alternatives: OTC sleep aids short-term, herbal (valerian cautiously).
- Pharmacologic Backup: Non-BZD anxiolytics (buspirone, SSRIs) if relapse anxiety.
- Red Flags: Severe symptoms → ER; rule out other causes.
- Success Metrics: Symptom scales < baseline; no PRN use.
Expected Outcomes:
- 50–80% success with protocol adherence.
- Improved cognition, mood, sleep long-term.
References: Ashton Manual (benzo.org.uk), NICE Guideline 215, VA/DoD BZD Guideline.
Consult a specialist (addiction psychiatrist) for complex cases. Track progress collaboratively!
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.